NOVA EYE MEDICAL LIMITED (EYE)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
EYE - NOVA EYE MEDICAL LIMITED
FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.58
Index:
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.13
01 Dec |
OPEN $0.14 |
HIGH $0.14 |
305,285 LOW $0.13 |
-0.010| OTHER COMPANIES IN THE SAME SECTOR | |||
| 4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . FPH . HLA . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -9.8 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 17.0 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 12.2 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -6.7 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -89.83 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -57.08 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -54.74 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -45.66 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -57.08 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -41.53 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -7.0 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 2 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 7 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 2.17 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 0.8 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 4.70 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 16 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 13 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | - |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
EYE STOCK CHART
FNArena News on EYE
Latest Medical Equipment & Devices News
| 1 |
Dr Boreham’s Crucible: Pro MedicusOct 23 2023 - Australia |
| 2 |
Dr Boreham’s Crucible: CyclopharmOct 09 2023 - Small Caps |
| 3 |
Dr Boreham’s Crucible: PainchekSep 11 2023 - Small Caps |
| 4 |
Margins Signal Integral Diagnostics RecoverySep 07 2023 - Australia |
| 5 |
ResMed: Finding A Base?Aug 15 2023 - Technicals |
| 6 |
August Turns ResMed Into Nigel NoMatesAug 09 2023 - Australia |
| 7 |
Dr Boreham’s Crucible: Lumos DiagnosticsJun 19 2023 - Small Caps |
| 8 |
Fisher & Paykel Healthcare: Lower Margin, Higher SpendingMay 30 2023 - Australia |
| 9 |
Dr Boreham’s Crucible: ImpedimedMay 08 2023 - Small Caps |
| 10 |
Treasure Chest: ResMed’s Benevolent MonopolyMay 01 2023 - Treasure Chest |
